The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

被引：0
|
作者：
Xu, Ning [1 ]
Ng, Nicole [1 ]
Li, Mingjie [1 ]
Yu, Erin [1 ]
Sanchez, Eric [1 ]
Bujarski, Sean [1 ]
Yin, Zhengyi [1 ]
Hekmati, Tara [1 ]
Field, Dylan [1 ]
Wang, Jasper [1 ]
Nassir, Isabella [1 ]
Yu, Janna [1 ]
Huang, Justin [1 ]
Daniely, David [1 ]
Wang, Cathy S. [1 ]
Chen, Haiming [1 ]
Berenson, James R. [1 ]
机构：
[1] Inst Myeloma Bone Canc Res, West Hollywood, CA USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131047
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1824
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Selective JAK1 blockade with Upadacitinib is effective in immune checkpoint inhibitor-induced colitis
    Ibraheim, H.
    Cozzetto, D.
    Olbei, M.
    Thomas, J. P.
    Korcsmaros, T.
    Lo, J. W.
    Powell, N.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i209 - i209
  • [42] THE JAK1/2 INHIBITOR RUXOLITINIB MODULATES ANTIGEN PRESENTING FUNCTIONS OF ACTIVATED PRIMARY B CELLS ON A METABOLIC LEVEL
    Theurich, S.
    Iltgen, J.
    Wennhold, K.
    Marquez, M. Garcia
    Rothschild, S.
    Schneider, B.
    Holtick, U.
    Thelen, M.
    Scheid, C.
    Becker, Hj
    Schloesser, H.
    Reuter, S.
    Vornhagen, A. Shimabukuro
    von Bergwelt-Baildon, M.
    HAEMATOLOGICA, 2016, 101 : 462 - 462
  • [43] PRECLINICAL ACTIVITY OF THE JAK1/2 INHIBITOR RUXOLITINIB ON MALIGNANT PLASMA CELL GROWTH AND SURVIVAL
    Burger, R.
    Bugdahn, T.
    Staudinger, M.
    Peipp, M.
    Guenther, A.
    Gramatzki, M.
    HAEMATOLOGICA, 2012, 97 : 438 - 439
  • [44] Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer
    Nunes-Xavier, Caroline E.
    Kildal, Wanja
    Kleppe, Andreas
    Danielsen, Havard E.
    Waehre, Hakon
    Llarena, Roberto
    Maelandsmo, Gunhild M.
    Fodstad, Oystein
    Pulido, Rafael
    Lopez, Jose I.
    PROSTATE, 2021, 81 (12): : 838 - 848
  • [45] Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome
    Huarte, Eduardo
    Peel, Michael T.
    Verbist, Katherine
    Fay, Brittany L.
    Bassett, Rachel
    Albeituni, Sabrin
    Nichols, Kim E.
    Smith, Paul A.
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [46] Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages
    Febvre-James, Marie
    Lecureur, Valerie
    Augagneur, Yu
    Mayati, Abdullah
    Fardel, Olivier
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 54 : 354 - 365
  • [47] An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms
    Curto-Garcia, Natalia
    Harrison, Claire N.
    FUTURE ONCOLOGY, 2018, 14 (02) : 137 - 150
  • [48] B7-H3, a checkpoint molecule, as a target for cancer immunotherapy
    Yang, Shuo
    Wei, Wei
    Zhao, Qi
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2020, 16 (11): : 1767 - 1773
  • [49] Treatment with Ruxolitinib, an orally bioavailable JAK1/2 inhibitor, prevents the onset of alopecia areata in C3H/HeJ mice
    Dai, Z.
    Xing, L.
    Jabbari, A.
    de Jong, A.
    Christiano, A. M.
    Clynes, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 : S106 - S106
  • [50] Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer
    Nunes-Xavier, Caroline E.
    Emaldi, Maite
    Guldvik, Ingrid J.
    Ramberg, Hakon
    Tasken, Kristin A.
    Maelandsmo, Gunhild M.
    Fodstad, Oystein
    Llarena, Roberto
    Pulido, Rafael
    Lopez, Jose I.
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 241
12345